<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224299</url>
  </required_header>
  <id_info>
    <org_study_id>MPS-16IPVFT05</org_study_id>
    <nct_id>NCT03224299</nct_id>
  </id_info>
  <brief_title>Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation</brief_title>
  <official_title>Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to compare the antimicrobial properties of an investigational&#xD;
      agent to an active control and a negative control when applied to specific body locations.&#xD;
      Testing will be performed according to the procedures outlined in the Food and Drug&#xD;
      Administration Tentative Final Monograph (TFM) for Effectiveness Testing of a Patient&#xD;
      Preoperative Skin Preparation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Actual">October 3, 2017</completion_date>
  <primary_completion_date type="Actual">August 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial Activity of the Investigational Products Compared to Control.</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate at 6 Hours Post-application</measure>
    <time_frame>6 hours</time_frame>
    <description>Number of participants with bacterial reduction greater than or equal to baseline (0)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Preoperative Skin Preparation</condition>
  <arm_group>
    <arm_group_label>Investigational Product #1 (IP1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Product #2 (IP2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ChloraPrep® - Hi-Lite Orange® applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sterile 0.9% saline applied with single use applicator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCT - clear</intervention_name>
    <description>Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear</description>
    <arm_group_label>Investigational Product #1 (IP1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCT- tinted</intervention_name>
    <description>Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted</description>
    <arm_group_label>Investigational Product #2 (IP2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ChloraPrep</intervention_name>
    <description>Active Control: ChloraPrep® - Hi-Lite Orange® applicator</description>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Negative Control: sterile 0.9% saline applied with single use applicator</description>
    <arm_group_label>Negative Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects may be of either sex, at least 18 years of age and of any race.&#xD;
&#xD;
          -  Subjects must be in good general health.&#xD;
&#xD;
          -  Subjects must read and sign an Informed Consent Form, Authorization to Use and&#xD;
             Disclose Protected Health Information Form, and the List of Restricted Products prior&#xD;
             to participating in the study.&#xD;
&#xD;
          -  Female subjects must complete a urine pregnancy test and have negative results&#xD;
             documented before proceeding to treatment with test materials.&#xD;
&#xD;
          -  All subjects must meet Screening Day microbial baseline requirements established by&#xD;
             the sponsor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergies or sensitivities to sunscreens, deodorants, laundry detergents,&#xD;
             fragrances, vinyl, latex (rubber), alcohols, soaps, metals, inks, dyes, tape&#xD;
             adhesives, or to common antibacterial agents found in soaps, lotions, ointments, or&#xD;
             particularly the active ingredients of the study product drug solutions.&#xD;
&#xD;
          -  Exposure of test sites to strong detergents, solvents, or other irritants within the&#xD;
             14-day product-restriction period or during the test period.&#xD;
&#xD;
          -  Exposure of test sites to antimicrobial agents, medicated soaps, medicated shampoos,&#xD;
             or medicated lotions, use of biocide-treated pools or hot tubs, use of tanning beds,&#xD;
             or sunbathing during the 14-day product-restriction period or during the test period.&#xD;
&#xD;
          -  Wear fabric softener-, bug repellent-, or UV-treated clothing during the 14-day&#xD;
             product-restriction period or during the test period.&#xD;
&#xD;
          -  Use of systemic or topical antibiotic medications, steroid medications (other than for&#xD;
             hormonal contraception or post-menopausal reasons), or any other product known to&#xD;
             affect the normal microbial flora of the skin during the 14-day product-restriction&#xD;
             period or during the test period.&#xD;
&#xD;
          -  A medical diagnosis of a physical condition, such as a current or recent severe&#xD;
             illness, mitral valve prolapse with a heart murmur, congenital heart disease,&#xD;
             hepatitis B, hepatitis C, an organ transplant, ports, or an immunocompromised&#xD;
             condition such as AIDS (or HIV positive), lupus, medicated diabetes (Type 1 or 2),&#xD;
             ulcerative colitis, Crohn's disease, asthma requiring daily medication, fibromyalgia&#xD;
             or multiple sclerosis (medicated).&#xD;
&#xD;
          -  Any tattoos or scars within 2 inches of the test sites; skin blemishes or warts may be&#xD;
             permissible with the specific approval of the Principal Investigator or consulting&#xD;
             physician.&#xD;
&#xD;
          -  Dermatoses, cuts, lesions, active skin rashes, scabs, breaks in the skin or other skin&#xD;
             disorders within 6 inches, on, or around the test sites.&#xD;
&#xD;
          -  A currently active skin disease or inflammatory skin condition (for example, contact&#xD;
             dermatitis, psoriasis, eczema) anywhere on the body that, in the opinion of the&#xD;
             Principal Investigator, would compromise subject safety or study integrity.&#xD;
&#xD;
          -  Subjects who receive an irritation score of 1 (any redness, swelling, rash, or dryness&#xD;
             present in any treatment area) for any individual skin condition prior to the&#xD;
             Screening Day baseline or Treatment Day baseline sample collection.&#xD;
&#xD;
          -  Participation in another clinical study in the past 30 days or current participation&#xD;
             in another clinical study at time of signing informed consent.&#xD;
&#xD;
          -  Showering, bathing, or swimming within the 72 hour period prior to sampling for&#xD;
             baseline screening, the test day, or throughout the test period.&#xD;
&#xD;
          -  Pregnancy, plans to become pregnant or impregnate a sexual partner within the pre-test&#xD;
             and test periods of the study, or nursing a child. All female subjects will be&#xD;
             required to complete a urine pregnancy test on the day of test material application,&#xD;
             prior to treatment. Both gender of subjects must be willing to use an acceptable&#xD;
             method of contraception to prevent pregnancy for at least 14 days immediately&#xD;
             preceding Treatment Day and throughout the duration of the study.&#xD;
&#xD;
          -  Any medical condition or use of any medications that, in the opinion of the Principal&#xD;
             Investigator or Consulting Physician, would preclude participation.&#xD;
&#xD;
          -  Unwillingness to fulfill the performance requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BioScience Laboratories</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioScience Laboratories</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <results_first_submitted>October 28, 2020</results_first_submitted>
  <results_first_submitted_qc>March 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2021</results_first_posted>
  <disposition_first_submitted>March 5, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 23, 2021</disposition_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03224299/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03224299/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Number of participants enrolled is 131. Each participant has up to 4 sites on their body treated with assigned products. Participants are treated bilaterally on the abdomen and/or groin based on passing screening criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Number of Participants</title>
          <description>Participants were treated with 2 of 4 study products (IP#1 [OCT/IPA-clear], IP#2 [OCT/IPA-tinted], AC [ChloraPrep Hi-Lite Orange], or NC [0.9% saline]), 1 on the left side of the body (abdomen and inguen received the same product) and 1 on the right (abdomen and inguen received the same product). Therefore, treatment groups are not discrete categories and cannot be described by treatment group.</description>
        </group>
        <group group_id="P2">
          <title>Number of Sites</title>
          <description>Test sites on body</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With IP#1</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With IP#2</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With AC</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated With NC</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were treated with 2 of 4 study products (IP#1 [OCT/IPA-clear], IP#2 [OCT/IPA-tinted], AC [ChloraPrep Hi-Lite Orange], or NC [0.9% saline]), 1 on the left side of the body (abdomen and groin received the same product) and 1 on the right (abdomen and groin received the same product). Therefore, treatment groups are not discrete categories and cannot be displayed by treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>Treated Subjects</title>
          <description>All treated subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antimicrobial Activity of the Investigational Products Compared to Control.</title>
        <time_frame>10 minutes</time_frame>
        <population>Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 30 seconds and 10 minutes.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational Product #1</title>
            <description>Octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear</description>
          </group>
          <group group_id="O2">
            <title>Investigational Product #2</title>
            <description>Octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted</description>
          </group>
          <group group_id="O3">
            <title>Active Control</title>
            <description>ChloraPrep® - Hi-Lite Orange® applicator</description>
          </group>
          <group group_id="O4">
            <title>Negative Control</title>
            <description>Sterile 0.9% saline applied with single use applicator</description>
          </group>
        </group_list>
        <measure>
          <title>Antimicrobial Activity of the Investigational Products Compared to Control.</title>
          <population>Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 30 seconds and 10 minutes.</population>
          <units>log10 CFU/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdomen Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="0.51"/>
                    <measurement group_id="O2" value="3.91" spread="0.52"/>
                    <measurement group_id="O3" value="3.87" spread="0.55"/>
                    <measurement group_id="O4" value="3.84" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen 30 seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="1.31"/>
                    <measurement group_id="O2" value="1.05" spread="1.23"/>
                    <measurement group_id="O3" value="1.34" spread="1.24"/>
                    <measurement group_id="O4" value="3.42" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen 10 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.30"/>
                    <measurement group_id="O2" value="0.91" spread="1.15"/>
                    <measurement group_id="O3" value="1.08" spread="1.10"/>
                    <measurement group_id="O4" value="3.12" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin Baseline Groin Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" spread="0.52"/>
                    <measurement group_id="O2" value="6.05" spread="0.59"/>
                    <measurement group_id="O3" value="6.03" spread="0.53"/>
                    <measurement group_id="O4" value="5.93" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin 30 seconds</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="1.26"/>
                    <measurement group_id="O2" value="3.03" spread="1.16"/>
                    <measurement group_id="O3" value="3.05" spread="1.19"/>
                    <measurement group_id="O4" value="5.11" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Groin 10 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="1.34"/>
                    <measurement group_id="O2" value="2.66" spread="1.37"/>
                    <measurement group_id="O3" value="2.66" spread="1.42"/>
                    <measurement group_id="O4" value="4.91" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes&#xD;
Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Abdomen 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>2.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>3.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Groin 10 minutes Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>2.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Abdomen 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.88</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Abdomen 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Abdomen 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.87</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Groin 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>2.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Groin 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Investigational product cannot be more than 0.05 log10 CFU/cm^2 less than the active control</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Groin 30 seconds Average treatment effect, calculated using a linear regression model for each body site, was used for primary analysis. In the model, the response was the post-treatment log10 bacterial counts and predictors were the treatment effect as a fixed effect and the pre-treatment log10 bacterial counts as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.62</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate at 6 Hours Post-application</title>
        <description>Number of participants with bacterial reduction greater than or equal to baseline (0)</description>
        <time_frame>6 hours</time_frame>
        <population>Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>IP#1</title>
            <description>Investigational Product #1 (IP1) Octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear</description>
          </group>
          <group group_id="O2">
            <title>IP#2</title>
            <description>Investigational Product #2 (IP2) Octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted</description>
          </group>
          <group group_id="O3">
            <title>Active Control</title>
            <description>Active Control (AC) - ChloraPrep® - Hi-Lite Orange® applicator</description>
          </group>
          <group group_id="O4">
            <title>Negative Control</title>
            <description>Negative Control (NC) - Sterile 0.9% saline applied with single use applicator</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate at 6 Hours Post-application</title>
          <description>Number of participants with bacterial reduction greater than or equal to baseline (0)</description>
          <population>Analysis only includes participants with required treatment day baseline bacterial counts at each anatomical site at baseline and non-missing data at 6 hours</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdomen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inguen</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IP#1</title>
          <description>Investigational Product #1 (IP1) Octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear</description>
        </group>
        <group group_id="E2">
          <title>IP#2</title>
          <description>Investigational Product #2 (IP2) Octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted</description>
        </group>
        <group group_id="E3">
          <title>Active Control</title>
          <description>Active Control (AC) - ChloraPrep® - Hi-Lite Orange® applicator</description>
        </group>
        <group group_id="E4">
          <title>Negative Control</title>
          <description>Negative Control (NC) - Sterile 0.9% saline applied with single use applicator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erin Zook</name_or_title>
      <organization>Becton Dickinson</organization>
      <phone>224-358-5019</phone>
      <email>erin.zook@bd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

